Transcript of Q1 - FY27 Earnings call held on August 03, 2026

CONCORD BIOTECH LIMITED B-1601-1602, B-wing Mondeal Heights, Iskcon Cross Road, S. G. Highway, Ahmedabad-380015, Gujarat. Phone : +91-79-68138700 Fax : +91-79-68138725 CIN No.: L24230GJ1984PLC007440 Email ID: complianceofficer@concordbiotech.com -------------------------------------------------------------------------------------------------------------------------------------------- August 07, 2026 To To The Manager, Listing Department General Manager, Listing Department National Stock Exchange of India Limited BSE Limited Plot No. C/1 G Block, Phiroze Jeejeebhoy Towers, Bandra-Kurla Complex, Bandra (East), Dalal Street, Mumbai -400 051 Mumbai – 400 001 Symbol: CONCORDBIO Scrip Code: 543960 Subject: Transcript of Q1 - FY27 Earnings call held on August 03, 2026 Dear Sir/Ma’am, In continuation of our letter dated August 03, 2026 regarding Earning Call Recording- For the first Quarter ended on June 30, 2026 and pursuant to Regulation 30 (6) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the transcript of the Earnings call for the said period is enclosed herewith and is also available on the website of the company at the following link. https://www.concordbiotech.com/investors Kindly take the same into your records and oblige. Thanking you, Yours faithfully For Concord Biotech Limited Paritosh Trivedi Company Secretary & Compliance Officer ACS 63623 Encl: as above ------------------------------------------------------------------------------------------------------------------------------------------ Regd. Office & Plant : 1482-1486, Trasad Road, Dholka, Dist. Ahmedabad-382225. (India) Phone : +91-2714-222604, 398200 Fax : +91-2714-222504 Website : www.concordbiotech.com “Concord Biotech Limited Q1 FY27 Earnings Conference Call” August 03, 2026 E&OE - This transcript is edited for factual errors. In case of discrepancy, the audio recording uploaded on the stock exchange on 03rd August 2026 will prevail. MANAGEMENT: MR. ANKUR VAID – JOINT MANAGING DIRECTOR AND CHIEF EXECUTIVE OFFICER – CONCORD BIOTECH LIMITED MR. RAVIRAJ KARIA – CHIEF FINANCIAL OFFICER – CONCORD BIOTECH LIMITED MR. PRAKASH SAJNANI – ASSISTANT VICE PRESIDENT, FINANCE – CONCORD BIOTECH LIMITED SGA – INVESTOR RELATIONS ADVISORS – CONCORD BIOTECH LIMITED MODERATOR: MR. NAMAN BAGRECHA – IIFL CAPITAL SERVICES LIMITED Page 1 of 14 Concord Biotech Limited August 03, 2026 Moderator: Ladies and gentlemen, good day, and welcome to Q1 FY27 Earnings Conference Call of Concord Biotech Limited hosted by IIFL Capital. This conference call may contain forward- looking statements about the company, which are based on beliefs, opinions and expectations of the company as on date of this call. These statements are not guarantee of future performance and involves risks and uncertainties that are difficult to predict. As a reminder, all participants lines will be in listen-only mode and there will be an opportunity for you to ask questions after the presentation concludes. Should you need assistance during this conference call, please signal an operator by pressing star, then zero on your touchtone phone. Please note that this conference is being recorded. I now hand over the conference to Mr. Naman Bagrecha from IIFL Capital. Thank you, and over to you, sir. Naman Bagrecha: Good afternoon, everyone. On behalf of IIFL Capital Services Limited, we welcome you all on Q1 FY27 Earnings Conference Call of Concord Biotech Limited. We will begin the call with opening commentary from Mr. Ankur Vaid joint Managing Director and Chief Executive Officer, followed by a Q&A session. Thank you, and over to you, sir. Ankur Vaid: Thank you, and a warm welcome to our Q1 FY27 Earnings Conference Call. Along with me, I have Raviraj, CFO; Prakash Sajnani, AVP, Finance for Concord Biotech; and SGA, our Investor Relations Partners. We are pleased to report a strong start to FY27 with Q1 FY27 revenues of INR257 crores, reflecting a healthy 26% year-on-year growth. As discussed previously, FY26 was a challenging year for Concord. We encountered multiple headwinds, including shifts in customer buying patterns, delays in obtaining CDSCO approval and tariff-related uncertainties that impacted customer procurement decisions for both current and future supplies. However, these challenges are not new to us. We have demonstrated in the past that we can successfully navigate similar situations and emerge stronger. FY27 has begun on a positive note with a robust first quarter performance. We remain confident of sustaining this momentum over the coming quarters on the back of business visibility in pipeline. Our confidence is underpinned the strength of our long-term growth strategy, our niche capabilities in fermentation-based products and our leadership position in key molecules in which we operate. These competitive strengths continue to position us well to capitalize on emerging opportunities and drive sustainable growth. Speaking of green shoots and highlights of our current quarter, growth in Q1 FY27 was broad-based with healthy contributions across our key product categories, including immunosuppressants, anti-infectives, oncology and antifungals rather than being driven by any single segment. Page 2 of 14 Concord Biotech Limited August 03, 2026 We continue to strengthen our relationships with existing customers, resulting in increased wallet share, higher market share and growth that outpaced the broader industry. During the quarter, we onboarded multiple new customers while also engaging in advanced discussions with several large customers for long-term and consistent product supplies. Our export business remained a key growth driver with export revenues increasing 46% year- on-year in Q1 FY27. This growth was broad-based across geographies, supported by rising inquiries from customers in major regulated and semi-regulated markets. The strengthening of our global regulatory approvals and compliance framework over the past year has significantly expanded our addressable market. In addition to the regulatory approvals received during FY26, we successfully completed inspection by ANVISA Brazil for our Limbasi facility and PPB Kenya and NDA Uganda for Unit 2 formulation facility at Valthera. These approvals enhance our ability to deepen our presence in existing markets while expanding into new geographies. During the quarter, we received ANDA approvals from U.S. FDA for mycophenolate mofetil and Tofacitinib tablets. These approvals, combined with our strong relationship with marquee customers, provide a meaningful runway for future growth. We have also successfully launched and commercialized fusidic acid in FY26, which is expected to contribute meaningfully to revenue growth during the current and next financial year. Our product pipeline remains robust with plans to launch 2 to 3 new products annually. There are a couple of products which are at advanced stages of development, and we expect commercialization of these products in the coming quarters. This steady pipeline supported by our R&D capabilities and regulatory expertise is expected to create a strong foundation for sustainable long-term growth. Another key milestone during the quarter was the commencement of commercial operations and sales through Stellon Biotech, our front-end distribution platform for formulation products in the U.S. While the business is currently at a nascent stage, we believe it has the potential to become a meaningful contributor to our growth over the coming years. Our injectable facility is also witnessing encouraging progress. Customer engagements and commercial discussions are at advanced stages and as facility scales up, we expect to contribute to both revenue growth and margin expansion. On the sustainability front, we are pleased to share that Concord has been awarded a silver medal by EcoVadis for its sustainability performance, placing us amongst the top 15% companies assessed globally. This recognition reflec [Showing first 8,000 characters — download PDF for full document]